Credits2

  2. Home
  3. Credits2
  4. Specialty Area
  5. Gastroenterology

 

Search

Results 1 - 31 of 31
New Frontiers in the Treatment of DMD Across the Age Spectrum
Expanding DMD Treatment Horizons: New Evidence
New Frontiers in the Treatment of DMD Across the Age Spectrum
Strides for DMD–Advancing Therapies, Empowering Patients Microlearning Library
Advances in the Unmet Needs of Myotonic Dystrophy Type 1 (DM1)
Addressing the Unmet Needs of Myotonic Dystrophy Type 1 (DM1)
9361-btc
Slide Download: Diagnosis, Assessment, and Therapeutic Management of BTC
9361-btc
Advances in the Diagnosis, Assessment, and Therapeutic Management of BTC
No image set
Hereditary Transthyretin Amyloidosis: Case Studies
No image set
hATTR Amyloidosis: You and Your Family
sma-journal-icon_263x0
Gene Therapy for SMA: An Emerging Treatment Option for a Devastating Disease
9834-0002
SMA: Data, Insights and Practice
9829-0001
From Bench to Bedside: Gene Therapy Approaches for Rare Diseases
9808-0004
What’s New in Spinal Muscular Atrophy? Reporting from Dallas
9808-0003
SMA Updates from Los Angeles
9808-0002
Updates in SMA and Gene Therapy from Arlington, VA
biosims-archmed icon1
Top Questions about Biosimilars in Gastroenterology
biosims-gastro2
Biosimilars and Patients with Inflammatory Bowel Disease
biosims-gastro1
Biosimilars: The New Era of Gastroenterology Management Considerations
IL-gastro-case3
Ulcerative Colitis: What Can You Expect When a Patient is Switched to a Biosimilar?
IL-gastro-case2
Biosimilars in Patients with Crohn’s Disease Failing an Initial Biologic
IL-gastro-case1
Innovator or Biosimilar for a Patient with Ulcerative Colitis?
IL-fund-case4
Interchangeability and Pharmacy-Level Substitution
IL-fund-case3
FDA Criteria: Biosimilar Approval, Manufacturing, & Naming
IL-fund-case2
What is the Difference Between a Biosimilar and a Generic?
IL-fund-case1
What is a Biologic?
biosims-full
Sorting it Out: Biologics, Biosimilars, Small Molecule Drugs, and Generics
biosims-full3
Health Care Providers’ Perspectives on Biosimilars: Based in Fact or Not?
biosims-green3
Pharmacovigilance and Biosimilars: Any Special Considerations?
biosims-full5
Interchangeability and Biosimilars: What will this Mean for Clinical Practice?
biosims-green8
Can a Biosimilar be Used for the Same Indications Approved for the Reference Biologic?
biosims-full7
Biosimilars: As Safe and Effective as the Reference Product?
biosims-green
Drift and the Manufacturing of Biologics: What is it and Does it Matter?
biosims-full8
Biosimilars in Clinical Practice: Interchangeability and Extrapolation

Search